Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Asymchem Laboratories (Tianjin) Co., Ltd. specializes in contract development and manufacturing services (CDMO) for the pharmaceutical industry, focusing on small molecule APIs and intermediates. With a strong presence in China and expanding operations in Europe and North America, Asymchem leverages its advanced manufacturing capabilities and regulatory expertise to attract global clients, driving revenue growth.
Asymchem generates revenue primarily through contract manufacturing and development services for pharmaceutical companies, capitalizing on its advanced facilities and regulatory compliance. The company benefits from strong pricing power due to its reputation for quality and reliability, along with economies of scale that enhance profitability.
New contract wins with major pharmaceutical companies
Expansion of manufacturing capacity in international markets
Regulatory approvals for new products
Market demand for outsourced pharmaceutical manufacturing
Regulatory changes impacting the pharmaceutical manufacturing landscape
Technological advancements that could disrupt traditional manufacturing processes
Increased competition from other CDMOs, particularly in Asia
Pricing pressure from clients seeking lower costs
Potential liquidity issues due to high capital expenditures (Capex of $1.3B)
Limited free cash flow generation (FCF Yield of 0.3%)
moderate - Asymchem's performance is somewhat linked to the overall health of the pharmaceutical industry, which can be influenced by GDP growth and healthcare spending.
Low - Asymchem's low debt levels (Debt/Equity of 0.01) minimize the impact of rising interest rates on financing costs, although higher rates could affect overall industry investment.
minimal - The company's strong balance sheet and low reliance on debt reduce vulnerability to credit market fluctuations.
growth - Asymchem's strong revenue growth and expanding market presence appeal to growth-focused investors.
moderate - The stock has shown significant returns (39.6% over 3 months) but may experience fluctuations based on contract wins and market conditions.